Regenxbio Inc. RGNX
We take great care to ensure that the data presented and summarized in this overview for REGENXBIO Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RGNX
View all-
Black Rock Inc. New York, NY8.61MShares$51.1 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.79MShares$28.5 Million2.9% of portfolio
-
Jpmorgan Chase & CO New York, NY4.14MShares$24.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.99MShares$17.7 Million0.0% of portfolio
-
State Street Corp Boston, MA2.19MShares$13 Million0.0% of portfolio
-
Morgan Stanley New York, NY2MShares$11.9 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.32MShares$7.85 Million0.01% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.19MShares$7.05 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.17MShares$6.96 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.09MShares$6.5 Million0.0% of portfolio
Latest Institutional Activity in RGNX
Top Purchases
Top Sells
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Insider Transactions at RGNX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 27
2025
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
30,752
+6.08%
|
$92,256
$3.76 P/Share
|
|
Feb 01
2025
|
Olivier Danos Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,452
-2.35%
|
$43,616
$8.07 P/Share
|
|
Feb 01
2025
|
Steve Pakola Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,263
-2.44%
|
$42,104
$8.07 P/Share
|
|
Feb 01
2025
|
Patrick J. Christmas Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,700
-2.92%
|
$37,600
$8.07 P/Share
|
|
Jan 02
2025
|
Patrick J. Christmas Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,395
-6.62%
|
$79,765
$7.73 P/Share
|
|
Jan 02
2025
|
Curran Simpson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
98,912
+27.79%
|
-
|
|
Jan 02
2025
|
Curran Simpson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,917
-7.01%
|
$83,419
$7.73 P/Share
|
|
Jan 02
2025
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,347
+20.38%
|
-
|
|
Jan 02
2025
|
Olivier Danos Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,630
-6.82%
|
$88,410
$7.73 P/Share
|
|
Jan 02
2025
|
Steve Pakola Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
64,293
+22.94%
|
-
|
|
Jan 02
2025
|
Steve Pakola Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,891
-8.39%
|
$97,237
$7.73 P/Share
|
|
Oct 01
2024
|
Argeris N Karabelas |
SELL
Open market or private sale
|
Direct |
10,000
-46.98%
|
$100,000
$10.11 P/Share
|
|
Oct 01
2024
|
Argeris N Karabelas |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+31.96%
|
$30,000
$3.76 P/Share
|
|
Sep 16
2024
|
Mitchell Chan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,869
+50.0%
|
-
|
|
Sep 03
2024
|
Argeris N Karabelas |
SELL
Open market or private sale
|
Direct |
10,000
-24.77%
|
$110,000
$11.92 P/Share
|
|
Sep 03
2024
|
Argeris N Karabelas |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+31.96%
|
$30,000
$3.76 P/Share
|
|
Aug 08
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
36,316
+7.56%
|
$0
$0.85 P/Share
|
|
Aug 01
2024
|
Steve Pakola Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,386
+26.07%
|
-
|
|
Aug 01
2024
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,867
+24.13%
|
-
|
|
Aug 01
2024
|
Curran Simpson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100
-0.06%
|
$1,500
$15.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 551K shares |
|---|---|
| Exercise of conversion of derivative security | 163K shares |
| Open market or private sale | 106K shares |
|---|---|
| Payment of exercise price or tax liability | 65.2K shares |